Gene-editing upstart lays out a $100M IPO with a plan to quickly leapfrog the leaders in their field
CRISPR/Cas9. TALEN. Zinc finger nuclease tech. The ARC nuclease.
You may have heard about those first 3 gene-editing platforms. But what’s an ARC nuclease?
ARCUS was put together by a group of scientists in North Carolina who have been making the pitch that they have a better way to accomplish the DNA hacking popularized 5 years ago by the original trio of startups: CRISPR Therapeutics, Editas, Intellia. Those biotechs are just now getting into the clinic, with Precision BioSciences coming in right behind with its own newly filed IND. They’re focused on a gene-edited allogeneic (off the shelf) CAR-T cell program targeting CD19 (not for the first time) which they plan on launching soon, with a Phase I/IIa clinical trial in patients with acute lymphoblastic leukemia and non-hodgkin lymphoma.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
